GO:0005001 transmembrane receptor protein tyrosine phosphatase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005001 describes the molecular function of transmembrane receptor protein tyrosine phosphatases (RPTPs), which combine signal binding with catalytic removal of phosphate from protein tyrosine residues.
• RPTPs are single-pass or multi-domain transmembrane enzymes that couple extracellular ligand recognition to intracellular phosphatase domains, thereby initiating changes in cell behavior.
• Key RPTP families include PTPRQ, PTPRK, PTPRZ1, LAR (PTPRF), and CD45 (PTPRC), each with distinct roles in development, metabolism, and immunity [1,5,6,7,8].
• Dysregulated RPTP activity is implicated in cancer, metabolic disorders, and immune pathologies, making these enzymes attractive therapeutic targets [4,5,6].
• Experimental modulation of RPTP activity, such as pH-responsive transmembrane agonists, can inhibit cancer-associated phenotypes.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential to dissect RPTP signaling and validate drug targets [2,3].
Description
Transmembrane receptor protein tyrosine phosphatases (RPTPs) are a family of cell-surface enzymes that dephosphorylate tyrosine residues on target proteins, thereby counteracting tyrosine kinase signaling. This molecular function, annotated as GO:0005001, is defined as combining with a signal and transmitting it across the membrane to initiate a change in cell activity via catalysis of the reaction: protein tyrosine phosphate + H2O = protein tyrosine + phosphate. RPTPs are critical for normal development, tissue homeostasis, and immune regulation, and their dysfunction is linked to cancer, diabetes, and neurological disorders [4,5,6]. Understanding RPTP activity at the molecular level is therefore essential for both basic biology and therapeutic development.
transmembrane receptor protein tyrosine phosphatase activity At A Glance
| GO ID | GO:0005001 |
|---|---|
| GO term | transmembrane receptor protein tyrosine phosphatase activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Signal reception and transmembrane transmission coupled to protein tyrosine dephosphorylation |
| Catalytic reaction | protein tyrosine phosphate + H2O = protein tyrosine + phosphate |
| Cellular location | Plasma membrane (transmembrane domain) |
| Representative genes | PTPRQ, PTPRK, PTPRZ1, PTPRF (LAR), PTPRC (CD45) |
What Is GO:0005001?
GO:0005001 (transmembrane receptor protein tyrosine phosphatase activity) is a molecular function that combines signal binding with transmembrane signal transduction and protein tyrosine phosphatase catalysis. In practical terms, a receptor on the cell surface binds a ligand, and this binding activates an intracellular phosphatase domain that removes phosphate groups from tyrosine residues on target proteins, thereby altering cellular signaling [1,2].
Why Is transmembrane receptor protein tyrosine phosphatase activity Important in Cell Biology?
RPTPs are key regulators of signal transduction pathways that control cell growth, differentiation, migration, and immune responses [1,5,7]. Their ability to counteract tyrosine kinases makes them central to the dynamic balance of phosphorylation, and their dysfunction contributes to a wide range of diseases including cancer, metabolic syndromes, and autoimmune conditions [4,5,6,8]. Studying GO:0005001 provides mechanistic insight into how extracellular cues are translated into intracellular signals and offers opportunities for targeted therapies [3,6].
• RPTPs regulate cell proliferation, differentiation, and survival by dephosphorylating tyrosine kinase substrates [1,7].
• PTPRQ mutations are associated with hearing loss and cancer progression.
• PTPRK functions as a tumor suppressor and regulates cell adhesion and growth factor signaling.
• PTPRZ1 is a potential target for cancer therapy and diagnosis, particularly in glioblastoma.
• LAR (PTPRF) modulates signaling by multiple receptor tyrosine kinases, impacting development and cancer.
• CD45 (PTPRC) is a essential regulator of T-cell and B-cell antigen receptor signaling.
• PTP1B (PTPN1) is a validated drug target for diabetes and obesity, highlighting the therapeutic potential of RPTPs.
• Modulating RPTP activity with small molecules or transmembrane agonists can inhibit cancer phenotypes.
• RPTPs are involved in neuronal development, synaptic plasticity, and neurodegeneration.
• CRISPR screens and knockout models are powerful tools to uncover RPTP gene functions in health and disease [2,3].
What Happens During transmembrane receptor protein tyrosine phosphatase activity?
Ligand binding and receptor activation
In simple terms: A signal molecule binds to the outside part of the receptor, switching it on.
RPTPs typically exist as dimers on the cell surface, and ligand binding or changes in the extracellular environment can induce conformational changes that relieve autoinhibition of the intracellular phosphatase domains. For example, pH-responsive transmembrane agonists can promote RPTP activity by altering dimerization.
Transmembrane signal transmission
In simple terms: The receptor passes the signal from outside to inside the cell.
The transmembrane domain couples extracellular ligand recognition to intracellular catalytic domains. Structural studies of RPTP homodimerization and heterodimerization reveal that the transmembrane region can mediate allosteric regulation, transmitting conformational changes across the membrane.
Catalytic dephosphorylation
In simple terms: The enzyme removes a phosphate group from target proteins.
The intracellular phosphatase domain catalyzes the hydrolysis of protein tyrosine phosphate to protein tyrosine and inorganic phosphate. This reaction reverses the action of tyrosine kinases, thereby modulating signaling pathways [1,7].
Substrate specificity and downstream effects
In simple terms: The enzyme targets specific proteins, leading to changes in cell behavior.
RPTPs exhibit substrate specificity determined by their extracellular and intracellular domains. For instance, LAR (PTPRF) modulates signaling by multiple receptor tyrosine kinases, affecting cell growth and differentiation. CD45 (PTPRC) dephosphorylates Src-family kinases to regulate immune cell activation.
Key Genes Involved in GO:0005001 transmembrane receptor protein tyrosine phosphatase activity
The following genes encode transmembrane receptor protein tyrosine phosphatases or are directly involved in their signaling pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPRQ | Receptor-type tyrosine phosphatase Q; regulates cell adhesion and motility | Implicated in hearing loss and cancer; potential biomarker |
| PTPRK | Receptor-type tyrosine phosphatase K; tumor suppressor, regulates cell adhesion | Associated with cancer and developmental disorders |
| PTPRZ1 | Receptor-type tyrosine phosphatase Z1; regulates neuronal development and glioma | Target for cancer therapy and diagnosis |
| PTPRF (LAR) | Leukocyte common antigen-related phosphatase; modulates RTK signaling | Role in development, cancer, and metabolic diseases |
| PTPRC (CD45) | Receptor-type tyrosine phosphatase C; essential for immune cell signaling | Marker for leukocytes; therapeutic target in autoimmune diseases |
| PTPN1 (PTP1B) | Non-receptor tyrosine phosphatase; negative regulator of insulin signaling | Drug target for diabetes and obesity |
| PTPRJ | Receptor-type tyrosine phosphatase J; regulates cell growth | Tumor suppressor in various cancers |
| PTPRG | Receptor-type tyrosine phosphatase G; involved in cell adhesion | Potential tumor suppressor |
| PTPRS | Receptor-type tyrosine phosphatase S; regulates neuronal development | Implicated in neurodevelopmental disorders |
| PTPRD | Receptor-type tyrosine phosphatase D; synaptic adhesion molecule | Associated with neuropsychiatric disorders |
| PTPRT | Receptor-type tyrosine phosphatase T; regulates STAT3 signaling | Mutated in colorectal and other cancers |
| PTPRU | Receptor-type tyrosine phosphatase U; regulates Wnt signaling | Role in development and cancer |
| PTPRZ1 | Receptor-type tyrosine phosphatase Z1; binds pleiotrophin | Promotes glioma progression |
| PTPRK | Receptor-type tyrosine phosphatase K; dephosphorylates EGFR | Modulates growth factor signaling |
| PTPRF | LAR family phosphatase; regulates insulin signaling | Linked to type 2 diabetes |
| PTPRC | CD45; regulates Src kinases | Target in leukemia and autoimmune diseases |
| PTPN1 | PTP1B; dephosphorylates insulin receptor | Validated drug target for metabolic diseases |
How Is transmembrane receptor protein tyrosine phosphatase activity Regulated?
RPTP activity is regulated at multiple levels, including ligand binding, dimerization, conformational changes, and post-translational modifications. For example, pH-responsive transmembrane agonists can enhance RPTP activity by promoting specific dimer conformations. Additionally, RPTPs can be regulated by phosphorylation, glycosylation, and proteolytic cleavage, which affect their localization and catalytic activity [1,5].
transmembrane receptor protein tyrosine phosphatase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTPRK | Cancer (tumor suppressor) | Knockout in cancer cell lines; xenograft models |
| PTPRZ1 | Glioblastoma | Overexpression and knockout in glioma cells; orthotopic models |
| PTPN1 | Type 2 diabetes, obesity | Knockout mice; insulin resistance models |
| PTPRC | Autoimmune diseases, leukemia | Knockout in immune cells; adoptive transfer models |
| PTPRF | Metabolic syndrome, cancer | Conditional knockout; point mutations in phosphatase domain |
Cancer
Dysregulation of RPTPs is frequently observed in cancer. PTPRK functions as a tumor suppressor, and its loss promotes cell proliferation and invasion. PTPRZ1 is overexpressed in glioblastoma and contributes to tumor growth and survival. Modulating RPTP activity with agonists can inhibit cancer-associated phenotypes, suggesting therapeutic potential.
Metabolic disorders
PTP1B (PTPN1) is a well-known negative regulator of insulin and leptin signaling, and its inhibition improves insulin sensitivity in diabetes and obesity models. Other RPTPs, such as LAR (PTPRF), also modulate insulin signaling and glucose homeostasis.
Immune and inflammatory diseases
CD45 (PTPRC) is critical for T-cell and B-cell activation, and its dysfunction is linked to autoimmune diseases and immunodeficiency. Targeting CD45 or its downstream pathways is an active area of therapeutic research.
Neurological disorders
RPTPs such as PTPRZ1 and PTPRS regulate neuronal development and synaptic function, and their mutations have been associated with neurodevelopmental and neurodegenerative conditions.
From transmembrane receptor protein tyrosine phosphatase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTPRK affect tumor growth? | PTPRK knockout in cancer cell lines and mouse xenografts |
| How does PTPRZ1 contribute to glioma progression? | PTPRZ1 overexpression and knockout in glioma stem cells |
| Can PTP1B inhibition improve insulin sensitivity? | PTPN1 knockout mice and point-mutation knock-in models |
| What is the role of CD45 phosphatase activity in T-cell signaling? | CD45 knockout and phosphatase-dead knock-in mice |
| How does LAR modulate RTK signaling? | LAR knockout and domain-specific knock-in models |
| Can transmembrane agonists enhance RPTP activity? | Overexpression of wild-type and mutant RPTPs; pH-responsive agonist treatment |
How to Study the transmembrane receptor protein tyrosine phosphatase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphatase activity assay | Catalytic activity of RPTPs | Validation of mutants and agonists [1,3] |
| Surface plasmon resonance (SPR) | Ligand binding affinity | Characterization of extracellular interactions |
| FRET/BRET | Conformational changes and dimerization | Studying activation mechanisms |
| CRISPR knockout screens | Gene function in phenotypes | Identifying RPTPs in cancer or immunity |
| Phosphoproteomics | Global tyrosine phosphorylation changes | Mapping RPTP substrate networks |
| Immunofluorescence | Subcellular localization | Assessing membrane expression and trafficking |
| Western blot | Protein expression and phosphorylation | Validating knockout or overexpression |
| qRT-PCR | mRNA expression levels | Measuring gene expression changes |
Phosphatase activity assays
In vitro phosphatase assays using synthetic phosphotyrosine substrates or immunoprecipitated RPTPs measure catalytic activity. These assays are essential to confirm the impact of mutations or agonists [1,3].
Structural and biophysical methods
Crystallography, NMR, and FRET-based approaches reveal how RPTP dimerization and conformational changes regulate activity. These methods help design small-molecule modulators.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify RPTPs that regulate specific phenotypes, such as cancer cell growth or immune activation [2,5].
Phosphoproteomics
Mass spectrometry-based phosphoproteomics quantifies changes in tyrosine phosphorylation upon RPTP manipulation, revealing downstream signaling networks.
How CRISPR Can Be Used to Study GO:0005001 transmembrane receptor protein tyrosine phosphatase activity
Knockout
CRISPR-Cas9 knockout of RPTP genes (e.g., PTPRK, PTPRZ1) is used to study loss-of-function phenotypes in cancer, metabolism, and immunity. Knockout cell lines and mouse models help determine whether a candidate gene is causally involved in a disease [5,6].
Point Mutation
Point mutations in the catalytic domain (e.g., cysteine-to-serine) can abolish phosphatase activity while preserving receptor structure. These models are valuable to separate catalytic from scaffolding functions [2,3].
Knock-in
Knock-in of tagged or mutant RPTPs (e.g., GFP-tagged PTPRZ1) allows real-time imaging and tracking of receptor localization and dynamics. Disease-associated mutations can be introduced to study their effects.
Overexpression
Overexpression of wild-type or mutant RPTPs in cell lines is used to investigate gain-of-function effects, such as enhanced phosphatase activity or ligand-independent signaling. This approach is useful for drug screening [3,4].
How EDITGENE Supports transmembrane receptor protein tyrosine phosphatase activity Research
Researchers studying transmembrane receptor protein tyrosine phosphatase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression models, as well as library screening and bioinformatics support, enabling rigorous functional studies of RPTPs.
Contact EDITGENE today to design your custom CRISPR model for transmembrane receptor protein tyrosine phosphatase activity research.
Frequently Asked Questions About transmembrane receptor protein tyrosine phosphatase activity
What is transmembrane receptor protein tyrosine phosphatase activity?
It is a molecular function (GO:0005001) where a cell-surface receptor binds a signal and transmits it across the membrane by removing phosphate groups from tyrosine residues on target proteins.
What genes are involved in transmembrane receptor protein tyrosine phosphatase activity?
Key genes include PTPRQ, PTPRK, PTPRZ1, PTPRF (LAR), and PTPRC (CD45), among others [1,5,6,7,8].
How does transmembrane receptor protein tyrosine phosphatase activity work?
The receptor binds a ligand, undergoes conformational changes, and activates its intracellular phosphatase domain to dephosphorylate substrates, thereby modulating signaling [2,3].
What diseases are associated with transmembrane receptor protein tyrosine phosphatases?
They are linked to cancer, diabetes, autoimmune diseases, and neurological disorders [4,5,6,8].
What is the role of PTPRK in cancer?
PTPRK acts as a tumor suppressor, and its loss promotes cell proliferation and invasion.
How is PTPRZ1 involved in glioblastoma?
PTPRZ1 is overexpressed in glioblastoma and promotes tumor growth and survival, making it a therapeutic target.
Can CRISPR be used to study transmembrane receptor protein tyrosine phosphatases?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect RPTP functions [2,3].
What is the catalytic mechanism of receptor tyrosine phosphatases?
They catalyze the hydrolysis of protein tyrosine phosphate to protein tyrosine and phosphate, reversing tyrosine kinase action.
How is transmembrane receptor protein tyrosine phosphatase activity regulated?
It is regulated by ligand binding, dimerization, conformational changes, and post-translational modifications [2,3].
What methods are used to measure transmembrane receptor protein tyrosine phosphatase activity?
Phosphatase assays, phosphoproteomics, FRET, and CRISPR screens are commonly used [1,2,7].
Conclusion
GO:0005001 transmembrane receptor protein tyrosine phosphatase activity is a fundamental molecular function that controls diverse signaling pathways. Its dysregulation contributes to cancer, metabolic, immune, and neurological diseases, making it a rich area for therapeutic development. CRISPR-based models and advanced screening methods are indispensable for uncovering the precise roles of RPTPs and translating these insights into clinical applications.
References
- 1. Zhang W et al.. 2022. Protein Tyrosine Phosphatase Receptor-type Q: Structure, Activity, and Implications in Human Disease.. Protein Pept Lett 29(7):567-573 PMID: 35546749
- 2. Rizzo S et al.. 2024. Identifying Transmembrane Interactions in Receptor Protein Tyrosine Phosphatase Homodimerization and Heterodimerization.. Methods Mol Biol 2743:195-209 PMID: 38147217
- 3. Rizzo S et al.. 2023. Promoting the activity of a receptor tyrosine phosphatase with a novel pH-responsive transmembrane agonist inhibits cancer-associated phenotypes.. Protein Sci 32(9):e4742 PMID: 37515426
- 4. Delibegović M et al.. 2024. Protein tyrosine phosphatase 1B in metabolic diseases and drug development.. Nat Rev Endocrinol 20(6):366-378 PMID: 38519567
- 5. Zheng C et al.. 2025. Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology.. J Transl Med 23(1):534 PMID: 40355891
- 6. Papadimitriou E et al.. 2023. Protein Tyrosine Phosphatase Receptor Zeta 1 as a Potential Target in Cancer Therapy and Diagnosis.. Int J Mol Sci 24(9) PMID: 37175798
- 7. Kulas DT et al.. 1996. The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases.. J Biol Chem 271(2):748-54 PMID: 8557682
- 8. Al Barashdi MA et al.. 2021. Protein tyrosine phosphatase receptor type C (PTPRC or CD45).. J Clin Pathol 74(9):548-552 PMID: 34039664
